The potential benefits of glucagon-like peptide-1 receptor agonists for diabetic retinopathy.

Baoying Pang, Huanran Zhou, Hongyu Kuang

Journal: Peptides 2018;100():123-126

PMID: 28807775

Full Text on Elsevier Science View on PubMed

Abstract

For a long time, diabetic retinopathy (DR) has been one of the most severe complications of diabetes. The early treatment of DR is not clearly recognized. The additional benefit of hypoglycemic agents for DR has become a new research field. Glucagon-like peptide-1 receptor (GLP-1R) has been shown to be widely expressed in tissues including retina. Glucagon-like peptide-1 receptor agonists (GLP-1RA) have been generally used in the treatment of diabetic patients. Studies shows that GLP-1RA could inhibit nerve damage by decrease apoptosis of nerve cells and activation of glial cells. In addition, GLP-1RA plays a protective role for tight junction (TJ) and cells of blood retinal barrier (BRB). It also protects retina from BRB damage. In this review, we discuss the potential protective mechanisms of GLP-1RA for DR beyond the hypoglycemic effects.

Address: Department of Endocrinology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.; Department of Endocrinology, The First Affiliated Hospital of Harbin Medical University, Harbin, China. Electronic address: [email protected].

DOI: 10.1016/j.peptides.2017.08.003

Link outs

Free resources

Medical:

https://medlineplus.gov/diabeticeyeproblems.html

Other Literature Sources:

Subscription / membership required

Full Text Sources:

MeSH Terms: Apoptosis, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor, Humans, Nerve Degeneration, Retina, Glucagon-Like Peptide-1 Receptor Agonists